TLR-8 ligands Library
ChemDiv’s TLR-8 Ligands Library contains 900 compounds.
TLR8 is expressed on the surface of endosomes and belong to the same subfamily of leukocyte PRRs. Together, TLR7 and TLR8 mediate recognition of purine-rich ssRNA to elicit an immune response to pathogens that are recognized in the endosome. Naturally derived viral uridine-rich ssRNAs include those of influenza and HIV. TLR7 and TLR8 are also implicated in the recognition of bacterial RNA. TLR8 is expressed in monocytes, macrophages, T cells, and most predominantly in myeloid DCs. TLR7 and TLR8 both signal through MyD88/MAL, including IL-1R–associatedkinase-4(IRAK-4) recruitment, to mediate cytokine and IFN production through NF-kB and IFN regulatory factor. In response to proinflammatory cytokine signaling, TLR7 and 8 transcription is induced via NF-kB.
The natural ligand of TLR7 and TLR8 is ssRNA. Small-molecule compounds such as imiquimod and resiquimod also activate both receptors and are the subject of adjuvantation research. Moreover, TLR8 agonist is used for ovarian cancer chemoimmunotherapy. [1]
[1] D. J. Dowling, “Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants,” ImmunoHorizons, vol. 2, no. 6, pp. 185–197, 2018, doi: 10.4049/immunohorizons.1700063.
TLR8 is expressed on the surface of endosomes and belong to the same subfamily of leukocyte PRRs. Together, TLR7 and TLR8 mediate recognition of purine-rich ssRNA to elicit an immune response to pathogens that are recognized in the endosome. Naturally derived viral uridine-rich ssRNAs include those of influenza and HIV. TLR7 and TLR8 are also implicated in the recognition of bacterial RNA. TLR8 is expressed in monocytes, macrophages, T cells, and most predominantly in myeloid DCs. TLR7 and TLR8 both signal through MyD88/MAL, including IL-1R–associatedkinase-4(IRAK-4) recruitment, to mediate cytokine and IFN production through NF-kB and IFN regulatory factor. In response to proinflammatory cytokine signaling, TLR7 and 8 transcription is induced via NF-kB.
The natural ligand of TLR7 and TLR8 is ssRNA. Small-molecule compounds such as imiquimod and resiquimod also activate both receptors and are the subject of adjuvantation research. Moreover, TLR8 agonist is used for ovarian cancer chemoimmunotherapy. [1]
[1] D. J. Dowling, “Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants,” ImmunoHorizons, vol. 2, no. 6, pp. 185–197, 2018, doi: 10.4049/immunohorizons.1700063.